Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice.
Open Access
- 1 March 1996
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 97 (5) , 1204-1210
- https://doi.org/10.1172/jci118534
Abstract
Interleukin-2 (IL-2) plays a pivotal role in the cellular and humoral immune responses directed against foreign antigens. We characterized the in vitro and in vivo properties of a chimeric protein consisting of mouse IL-2 fused to the mouse IgG2b Fc domains. This fusion protein binds to IL-2 and Fc receptors and supports IL-2-dependent cell proliferation but does not mediate lysis of IL-2 receptor-positive cells in the presence of murine complement in vitro. However, in vivo the IL2-IgG2b fusion protein suppresses both cellular and humoral immune responses after immunization with sheep erythrocytes. Surprisingly, delayed hypersensitivity is inhibited despite a dramatic increase of splenic CD3+ and NK1.1+ lymphocytes, indicating that altered homing of IL2-IgG2b-activated lymphocytes rather than cytolysis prevents these cells from accumulating in areas of inflammation. Although in vitro the IL2-IgG2b fusion protein does not alter proliferation of B cells in response to mitogenic stimulation, IgM production in response to sheep erythrocytes is profoundly inhibited in mice treated with the IL2-IgG2b fusion protein. Since no side effects are observed, the IL2-IgG2b fusion protein may expand the therapeutic repertoire of reagents used for the treatment of allograft rejection and autoimmune diseases.Keywords
This publication has 25 references indexed in Scilit:
- RAT INTERLEUKIN-2 IMMUNOGLOBULIN M FUSION PROTEINS ARE CYTOTOXIC IN VITRO FOR CELLS EXPRESSING THE IL-2 RECEPTOR AND CAN ABOLISH CELL-MEDIATED IMMUNITY IN VIVOTransplantation, 1994
- Treatment of Murine Lupus with CTLA4IgScience, 1994
- Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation.The Journal of Experimental Medicine, 1993
- Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation MoleculeScience, 1992
- Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lgScience, 1992
- lnterleukin-2 programs mouse αβ T lymphocytes for apoptosisNature, 1991
- CLUSTER-FUNCTION RELATIONSHIP OF RAT-ANTIMOUSE P55 IL-2 RECEPTOR MONOCLONAL ANTIBODIES IN VITRO STUDIES OF THE CTL-L2 MOUSE CELL LINE AND IN VIVO STUDIES IN A DELAYED-TYPE HYPERSENSITIVITY MODEL IN MICETransplantation, 1991
- Randomized Controlled Trial of a Monoclonal Antibody against the Interleukin-2 Receptor (33B3.1) as Compared with Rabbit Antithymocyte Globulin for Prophylaxis against Rejection of Renal AllograftsNew England Journal of Medicine, 1990
- POLYCLONAL RABBIT GAMMA GLOBULINS AGAINST A HUMAN CYTOTOXIC CD4 T CELL CLONETransplantation, 1989
- Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).Journal of Histochemistry & Cytochemistry, 1984